Release Date: 2024-06-12

Hyperthermia: Causes, Symptoms, Prevention and Treatment

Omer Isik (Author)

Release Date: 2024-06-12

Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells. The objective of this treatment is to raise the temperature in tumor up to such a therapeutic level that cell death occurs. Hyperthermia, the use of elevated temperatures to treat cancer, has emerged [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inImmunotherapy in Human Cancers
    First Page229
    Last Page238
    DOIhttps://doi.org/10.69860/nobel.9786053359388.16
    Page Count10
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells. The objective of this treatment is to raise the temperature in tumor up to such a therapeutic level that cell death occurs. Hyperthermia, the use of elevated temperatures to treat cancer, has emerged as a promising adjuvant therapy. By raising the temperature of tumor tissues to 40-45°C, hyperthermia enhances the effectiveness of radiation and chemotherapy. This therapeutic approach can damage and kill cancer cells with minimal harm to normal tissues, primarily by causing protein denaturation and disruption of cellular functions. Advances in hyperthermia techniques, including localized and whole-body applications, are improving targeting precision and patient outcomes. Clinical studies have shown that hyperthermia can increase tumor sensitivity to other treatments, leading to improved response rates and survival in various cancers. Despite its potential, challenges remain in optimizing delivery methods and integrating hyperthermia into standard treatment protocols.

    Omer Isik (Author)
    PhD, Assistant Professor, Istanbul Arel University
    https://orcid.org/0000-0002-0726-9446
    3Assistant Prosessor Ömer Işık Bachelor’S Degree. Education.gaziantep university engineering faculty(1999-2005) Master Degree. Electrical and electronics engineering specilization. Fatih University Department of Electrical and electronics engineering (2006-2010) Doctoral. Electrical and electronics engineering specilization. Fatih University Department of Electrical and electronics engineering (2010-2015) Departrment of Electrical and electronics engineering. Gelişim university(2015-2016) Deparrment of Electrical and electronics engineering. Beykent uiversity(2019-2021) Department of Electrical and electronics engineering. Arel univeristy(2021-Present)

    • Sung, H., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021. 71(3): p. 209-249.

    • Woodard, G.A., K.D. Jones, and D.M. Jablons, Lung cancer staging and prognosis. Lung cancer: treatment and research, 2016: p. 47-75.

    • Engels, E.A., Epidemiology of thymoma and associated malignancies. Journal of Thoracic Oncology, 2010. 5(10): p. S260-S265.

    • Bueno, R., et al., Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature genetics, 2016. 48(4): p. 407-416.

    • Siegel, R.L., K.D. Miller, H.E. Fuchs, and A. Jemal, Cancer statistics, 2021. Ca Cancer J Clin, 2021. 71(1): p. 7-33.

    • Goldstraw, P., et al., The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology, 2007. 2(8): p. 706-714.

    • Langer, C.J., et al., Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The lancet oncology, 2016. 17(11): p. 1497-1508.

    • Forde, P.M., et al., Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New England Journal of Medicine, 2022. 386(21): p. 1973-1985.

    • Provencio, M., et al., Perioperative nivolumab and chemotherapy in stage III non–smallcell lung cancer. New England Journal of Medicine, 2023. 389(6): p. 504-513.

    • Lu, S., et al., Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA, 2024. 331(3): p. 201-211.

    • Cascone, T., et al., LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology, 2023. 34: p. S1295.

    • Wakelee, H., et al., Perioperative pembrolizumab for early-stage non–small-cell lung cancer. New England Journal of Medicine, 2023. 389(6): p. 491-503.

    • Heymach, J.V., et al., Perioperative durvalumab for resectable non–small-cell lung cancer. New England Journal of Medicine, 2023. 389(18): p. 1672-1684.

    • Lei, J., et al., Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for chinese patients with resectable stage IIIA or IIIB (T3N2) non–small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA oncology, 2023. 9(10): p. 1348-1355.

    • Pignon, J.-P., et al., Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, in Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]. 2008, Centre for Reviews and Dissemination (UK).

    • Felip, E., et al., Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB– IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet, 2021. 398(10308): p. 1344-1357.

    • O’Brien, M., et al., Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. The Lancet Oncology, 2022. 23(10): p. 1274-1286.

    • Aupérin, A., et al., Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet], 2010.

    • Spigel, D.R., et al., Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. Journal of Clinical Oncology, 2022. 40(12): p. 1301.

    • Borghaei, H., et al., Nivolumab versus docetaxel in advanced nonsquamous non–smallcell lung cancer. New England Journal of Medicine, 2015. 373(17): p. 1627-1639.

    • Mazieres, J., et al., Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology, 2019. 30(8): p. 1321-1328.

    • Herbst, R.S., et al., Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. New England Journal of Medicine, 2020. 383(14): p. 1328-1339.

    • Socinski, M.A., et al., Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. New England Journal of Medicine, 2018. 378(24): p. 2288-2301.

    • West, H., et al., Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology, 2019. 20(7): p. 924-937.

    • Barlesi, F., et al., Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Annals of Oncology, 2016. 27: p. vi581.

    • Sezer, A., et al., Cemiplimab monotherapy for first-line treatment of advanced non-smallcell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. The Lancet, 2021. 397(10274): p. 592-604.

    • Gogishvili, M., et al., Cemiplimab plus chemotherapy versus chemotherapy alone in nonsmall cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nature Medicine, 2022. 28(11): p. 2374-2380.

    • Paz-Ares, L.G., et al., First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. Journal of Thoracic Oncology, 2022. 17(2): p. 289-308.

    • Reck, M., et al., Nivolumab (NIVO)+ ipilimumab (IPI)+ 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. 2020, American Society of Clinical Oncology.

    • Brahmer, J., et al., Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New England Journal of Medicine, 2015. 373(2): p. 123-135.

    • Reck, M., et al., Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%. Journal of Clinical Oncology, 2021. 39(21): p. 2339.

    • Mok, T.S., et al., Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet, 2019. 393(10183): p. 1819-1830.

    • Gandhi, L., et al., Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. New England journal of medicine, 2018. 378(22): p. 2078-2092.

    • Paz-Ares, L.G., et al., Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). 2018, American Society of Clinical Oncology.

    • Herbst, R.S., et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, 2016. 387(10027): p. 1540-1550.

    • Johnson, M.L., et al., Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study. Journal of Clinical Oncology, 2023. 41(6): p. 1213-1227.

    • Riano, I., S.R. Patel, S.V. Liu, and N. Duma, Evidence to date: evaluating pembrolizumab in the treatment of extensive-stage small-cell lung cancer. Clinics and Practice, 2021. 11(3): p. 441-454.

    • Goldman, J.W., et al., Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 2021. 22(1): p. 51-65.

    • Jakopovic, M., et al., Immunotherapy for thymoma. Journal of thoracic disease, 2020. 12(12): p. 7635.

    • Lettieri, S., et al., The evolving landscape of the molecular epidemiology of malignant pleural mesothelioma. Journal of Clinical Medicine, 2021. 10(5): p. 1034.

    • Baas, P., et al., First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet, 2021. 397(10272): p. 375-386.

    • Fennell, D.A., et al., Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 2021. 22(11): p. 1530-1540.

    • Scherpereel, A., et al., Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. The Lancet Oncology, 2019. 20(2): p. 239-253.

    • . Disselhorst, M.J., et al., Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. The Lancet Respiratory Medicine, 2019. 7(3): p. 260-270.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!